The International Liver Congress 2015 (ILC 2015), the 50th annual meeting of the European Association for the Study of the Liver (EASL), took place in Vienna, Austria, 22nd-26th April 2015.

Conference highlights

Advanced liver disease

Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease.

New EASL guidelines

European liver specialists prioritise interferon-free hepatitis C treatment.

Previous treatment failure

Merck HCV combination effective after failure of first generation of direct-acting antivirals.


aidsmap news from ILC 2015

← First12Next →

Editors' picks from other sources

News bulletins

Sign up for our email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Official conference website

Find out more and view the programme on the International Liver Congress website.

Visit the conference website >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.